Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
New technologies for biomarker discovery in multiple sclerosis.
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System.
Oral Agent Outcomes
Enrollment complete for cannabinoid MS study
Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.
Clonally expanded mitochondrial DNA deletions within the choroid plexus in multiple sclerosis.
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.
Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.
Epstein-Barr virus, latitude and multiple sclerosis.
A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis.
1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis.
FDA approves injectable drug to treat opioid-dependent patients
Effects of sleep and wake on oligodendrocytes and their precursors.
Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis.
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
No quiet surrender: molecular guardians in multiple sclerosis brain.
Plasma chemerin levels in patients with multiple sclerosis.
Pain and multiple sclerosis: pathophysiology and treatment.
Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.
Studies of EN-1639A (naltrexone): a new narcotic antagonist.
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI.
Pages
« first
‹ previous
…
145
146
147
148
149
150
151
152
153
…
next ›
last »